Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Chief Commercial Officer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,647 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 1,929 · Balance 67,303 Row 2 · 2026-10-01 · Exercise / conversion · Acquired 1,668 · Balance 68,971 Row 3 · 2026-10-01 · Exercise / conversion · Acquired 2,527 · Balance 71,498 Row 4 · 2026-10-01 · Exercise / conversion · Acquired 1,292 · Balance 72,790 Row 5 · 2026-10-01 · Tax withholding · Disposed 3,143 · Balance 69,647 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-10-01 · Exercise / conversion · Disposed 1,929 · Balance 0 F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 1,668 · Balance 0 F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 10,105 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 2,527 · Balance 10,105 F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,754 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 1,292 · Balance 7,754 F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on November 7, 2022 that vested over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vested in equal quarterly installments over the remaining three-year period thereafter.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on December 13, 2023 that vested over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vested in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F6: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on April 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 15,428 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · derivative · entry 9 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,428 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a performance-based restricted stock unit award granted on June 7, 2023, with a performance metric and 2-year vest period that was achieved. The shares vested on January 1, 2026. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,786 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 10,162 | $102.14 | $1,037,946.68 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,870 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 2,526 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 5,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 15,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 22:59 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-26-000002 · wk-form4_1767653972.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000010 · wk-form4_1766017178.xml · derivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,804 Underlying: Common Stock · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 594 | $102.67 | $60,985.98 |
DisclosureSEC source: 0001871615-25-000010 · wk-form4_1766017178.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,795 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:19 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000010 · wk-form4_1766017178.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 2,964 | $106.71 | $316,282.81 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 11 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,987 F11 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.500 to $106.990. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 400 | $105.99 | $42,394.52 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 10 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,951 F10 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.415 to $106.390. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 6,555 | $103.97 | $681,534.49 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 9 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,351 F9 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.725 to $104.510. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 3,414 | $103.25 | $352,505.06 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 8 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,906 F8 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.720 to $103.710. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 11,969 | $102.09 | $1,221,970.27 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,320 F7 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.720 to $102.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 4,084 | $101.40 | $414,128.63 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,289 F6 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.710 to $101.695. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 228 | $106.63 | $24,312.14 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,373 F5 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $106.450 to $106.735. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 244 | $104.10 | $25,400.03 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,601 F4 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.010 to $104.200. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 372 | $103.48 | $38,495.12 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,845 F3 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.005 to $103.860. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 744 | $102.31 | $76,115.66 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,217 F2 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.810 to $102.700. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 02:37 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCommon Stock | 478 | $101.43 | $48,482.44 |
DisclosureSEC source: 0001871615-25-000008 · wk-form4_1765247852.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,961 F1 · price: Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.770 to $101.750. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 9,954 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · derivative · entry 7 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,210 Underlying: Common Stock · 9,954 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This represents a restricted stock unit award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vests on October 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · derivative · entry 6 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,669 Underlying: Common Stock · 1,668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · derivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,714 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 5,740 | $62.65 | $359,611.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · nonDerivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,439 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 9,954 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,225 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:05 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000006 · wk-form4_1759449909.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:15 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000004 · wk-form4_1758143712.xml · derivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,206 Underlying: Common Stock · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024. The remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:15 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 594 | $54.79 | $32,545.26 |
DisclosureSEC source: 0001871615-25-000004 · wk-form4_1758143712.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,629 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 21:15 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001871615-25-000004 · wk-form4_1758143712.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000221 · wk-form4_1751505841.xml · derivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,337 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,929 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000221 · wk-form4_1751505841.xml · derivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,642 Underlying: Common Stock · 1,929 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vests in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,532 | $50.71 | $77,687.72 |
DisclosureSEC source: 0001576280-25-000221 · wk-form4_1751505841.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,821 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000221 · wk-form4_1751505841.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:24 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000221 · wk-form4_1751505841.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,402 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000187 · wk-form4_1750118577.xml · derivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,608 Underlying: Common Stock · 1,402 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F5 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 4,879 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000187 · wk-form4_1750118577.xml · derivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,879 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock unit vested 25% of the shares subject to such award on June 15, 2022. The remaining 75% of the shares subject to such award vests in substantially equal installments on each anniversary of June 15, 2022 during the three-year period thereafter. F3 · derivative.expiration_date: Not applicable to Restricted Stock Units Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 2,675 | $49.29 | $131,850.75 |
DisclosureSEC source: 0001576280-25-000187 · wk-form4_1750118577.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,757 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000187 · wk-form4_1750118577.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2025 Filed Jun 17, 2025 00:03 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 4,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000187 · wk-form4_1750118577.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000116 · wk-form4_1743629728.xml · derivative · entry 5 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,004 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This represents a restricted stock unit award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,928 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000116 · wk-form4_1743629728.xml · derivative · entry 4 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,571 Underlying: Common Stock · 1,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on November 7, 2022 that vests over a four-year period. 25% of the shares subject to such award vested on October 1, 2023 and the remaining 75% of the shares vest in equal quarterly installments over the remaining three-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 1,106 | $42.47 | $46,971.82 |
DisclosureSEC source: 0001576280-25-000116 · wk-form4_1743629728.xml · nonDerivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,292 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000116 · wk-form4_1743629728.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 21:35 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,928 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000116 · wk-form4_1743629728.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,731 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionRestricted Stock Units · Derivative | 1,401 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000092 · wk-form4_1742333181.xml · derivative · entry 3 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,010 Underlying: Common Stock · 1,401 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vest in equal quarterly installments over the remaining two-year period thereafter. F3 · derivative.expiration_date: Not applicable for Restricted Stock Units. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Tax withholdingCommon Stock | 387 | $42.89 | $16,598.43 |
DisclosureSEC source: 0001576280-25-000092 · wk-form4_1742333181.xml · nonDerivative · entry 2 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,803 F1 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document |
| March 15, 2025 Filed Mar 18, 2025 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCommon Stock | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001576280-25-000092 · wk-form4_1742333181.xml · nonDerivative · entry 1 Freeman Chris · CIK 0001871615 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,190 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.